Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 4:11 pm Purchase |
2020-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
Venrock Healthcare Capital Partners II, L.P. | 474,675 9.990% |
474,675 (New Position) |
Filing History |
| 2021-02-16 4:10 pm Sale |
2020-12-31 | 13G | Surface Oncology, Inc. SURF |
Venrock Healthcare Capital Partners II, L.P. | 1,442,895 3.500% |
-2,435,000 (-62.79%) |
Filing History |
| 2021-02-16 4:10 pm Sale |
2020-12-31 | 13G | Relmada Therapeutics, Inc. RLMD |
Venrock Healthcare Capital Partners II, L.P. | 668,440 4.100% |
-214,374 (-24.28%) |
Filing History |
| 2021-02-16 4:09 pm Purchase |
2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
Venrock Healthcare Capital Partners II, L.P. | 2,588,941 7.300% |
963,231 (+59.25%) |
Filing History |
| 2021-02-16 4:06 pm Purchase |
2020-12-31 | 13G | Athira Pharma, Inc. ATHA |
Venrock Healthcare Capital Partners II, L.P. | 1,691,623 5.200% |
34,000 (+2.05%) |
Filing History |
| 2020-11-16 4:05 pm Purchase |
2020-11-06 | 13G | Athira Pharma, Inc. ATHA |
Venrock Healthcare Capital Partners II, L.P. | 1,657,623 5.100% |
1,657,623 (New Position) |
Filing History |
| 2020-08-18 7:20 pm Purchase |
2020-08-13 | 13G | UNUM THERAPEUTICS INC UMRX |
Venrock Healthcare Capital Partners II, L.P. | 4,355,273 11.400% |
2,468,055 (+130.78%) |
Filing History |
| 2020-07-30 7:05 pm Purchase |
2020-07-20 | 13G | IMV Inc. IMV |
Venrock Healthcare Capital Partners II, L.P. | 31,500,000 5.100% |
31,500,000 (New Position) |
Filing History |
| 2020-07-20 4:07 pm Purchase |
2020-07-09 | 13G | UNUM THERAPEUTICS INC UMRX |
Venrock Healthcare Capital Partners II, L.P. | 1,887,218 5.000% |
1,887,218 (New Position) |
Filing History |
| 2020-06-25 4:06 pm Purchase |
2020-06-15 | 13D | Altimmune, Inc. ALT |
Venrock Healthcare Capital Partners II, L.P. | 4,500,000 20.800% |
1,500,000 (+50.00%) |
Filing History |
| 2020-06-12 4:01 pm Purchase |
2020-06-02 | 13G | Humanigen, Inc. HGEN |
Venrock Healthcare Capital Partners II, L.P. | 3,448,276 8.300% |
3,448,276 (New Position) |
Filing History |
| 2020-06-01 4:05 pm Purchase |
2020-05-20 | 13G | Altimmune, Inc. ALT |
Venrock Healthcare Capital Partners II, L.P. | 3,000,000 19.300% |
3,000,000 (New Position) |
Filing History |
| 2020-05-29 4:05 pm Purchase |
2020-05-19 | 13G | Surface Oncology, Inc. SURF |
Venrock Healthcare Capital Partners II, L.P. | 3,877,895 9.900% |
3,877,895 (New Position) |
Filing History |